KRAS and neoplasm: Accordingly, the marked and significant reduction of the tumour sizes by treatment with the αEGFR-mAB-P/KRAS-siRNA/P nanostructures can be explained by a combination of reduced proliferation and increased apoptosis in the respective tumours.